Characteristics of patients undergoing blood and plasma sampling during and after paclitaxel infusion
| Characteristic | Patient 1 | Patient 2 | Patient 3 |
|---|---|---|---|
| Baseline screening | |||
| Age (years) | 64 | 62 | 51 |
| Gender | Female | Male | Female |
| Height (cm) | 164 | 167 | 168 |
| Weight (kg) | 69.7 | 64.4 | 61.4 |
| BSA (m2) | 1.76 | 1.72 | 1.70 |
| WHO PS | 1 | 1 | 0 |
| Primary tumor | NSCLC | Bladder | ACUP |
| Pretherapy clinical chemistry values | |||
| Serum creatinine (μM) | 82 | 93 | 69 |
| Total bilirubin (μM) | 8.0 | 8.0 | 3.0 |
| ASAT (units/l) | 10 | 18 | 26 |
| ALAT (units/l) | 16 | 12 | 31 |
| Total protein (mg/ml) | 78 | 74 | 72 |
| Serum albumin (mg/ml) | 43 | 36 | 45 |
| Worst observed toxicity (according to NCI-CTC grading) | |||
| 135 mg/m2 | |||
| 175 mg/m2 | |||
| 225 mg/m2 | Nausea 2 | WBC 3/ANC 2 | Nausea 1 |
BSA, body surface area; WHO PS, World Health Organization performance status; NSCLC, non-small cell lung cancer; ACUP, adenocarcinoma of unknown primary origin; ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; NCI-CTC, National Cancer Institute common toxicity criteria; WBC, white blood cell count (leukocytopenia); ANC, absolute neutrophil count (neutropenia).